• 3-Deazaneplanocin (DZNep): Epigenetic Modulator in Cancer Mo

  2026-04-22

  3-Deazaneplanocin (DZNep) is a potent competitive inhibitor of S-adenosylhomocysteine hydrolase and suppresses the histone methyltransferase EZH2, leading to loss of H3K27 trimethylation. It induces apoptosis and cell cycle inhibitors in acute myeloid leukemia cell lines, and restricts tumorigenicity in hepatocellular carcinoma models. DZNep’s robust activity and protocol flexibility make it a valuable tool in oncology and metabolic disease research.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-04-22

  This study reveals that naturally occurring angiotensin peptide fragments, including N-terminally truncated variants, significantly enhance the binding of the SARS-CoV-2 spike protein to its alternative receptor AXL. These findings identify a novel molecular mechanism at the intersection of blood pressure regulation and viral pathogenesis, with implications for both COVID-19 research and renin-angiotensin system modeling.

• EGTA in Endothelial Inflammation: Advanced Calcium Chelation

  2026-04-21

  Explore the specialized use of EGTA (egtaizic acid) as a selective calcium chelator in dissecting endothelial cell inflammation and atherosclerosis. This article uniquely bridges mechanistic insights from recent research with practical assay design, moving beyond traditional neuroprotection paradigms.

• Divergent Effects of Amyloid-β on Human Synapses in Live Bra

  2026-04-21

  This study pioneers real-time investigation of amyloid-β (Aβ) and tau effects on synaptic health using live human brain slice cultures. It reveals distinct synaptic responses to physiological versus pathological Aβ, providing new insights for Alzheimer’s disease research and highlighting critical methodological advances.

• Dabigatran in Thromboembolism: Efficacy, Safety, and Researc

  2026-04-20

  Enriquez et al. (2015) comprehensively reviewed the clinical and pharmacological profile of dabigatran for the prevention and treatment of thromboembolic disorders. This pivotal analysis highlights dabigatran’s advantages over traditional vitamin K antagonists—most notably its predictable pharmacokinetics, reduced monitoring burden, and improved safety profile in key indications such as stroke prevention in atrial fibrillation and venous thromboembolism. The findings inform both clinical and translational research applications.

• Firefly Luciferase mRNA: Redefining Translational Assays

  2026-04-20

  This thought-leadership article explores how EZ Cap™ Firefly Luciferase mRNA (5-moUTP) catalyzes a new era in translational research by integrating advanced chemical modifications with state-of-the-art delivery strategies. Drawing on Yufei Xia’s recent thesis and the latest literature, we dissect mechanistic insights, compare delivery platforms, and provide actionable guidance for researchers aiming to unlock high-fidelity, immune-evading bioluminescent reporter assays.

• Perphenazine: Dopamine D2 Receptor Antagonist in Research Wo

  2026-04-19

  Perphenazine is much more than a classical dopamine D2 receptor antagonist: it offers robust, multi-receptor engagement for both neuropharmacology and host-directed antibacterial assays. Leverage APExBIO's rigorously characterized Perphenazine for mitochondria-mediated cell death studies, opioid tolerance suppression, and advanced immunological research.

• Dynasore Protocols: Practical Guidance for Endocytosis Resea

  2026-04-18

  Dynasore is a well-characterized, reversible inhibitor of dynamin GTPases, offering researchers a precise tool for dissecting dynamin-dependent endocytosis and vesicle trafficking. It is best suited for applications requiring the acute, dose-controlled blockade of endocytic pathways, but is not indicated for studies reliant on long-term or irreversible inhibition of membrane dynamics.

• HDAC6-Mediated α-Tubulin Lactylation Regulates Microtubule D

  2026-04-17

  This study uncovers α-tubulin lactylation as a reversible post-translational modification, catalyzed primarily by HDAC6, and demonstrates its ability to enhance microtubule dynamics in neurons. The findings establish a mechanistic link between cellular metabolism—via lactate levels—and cytoskeletal regulation, with implications for understanding neuronal development and microtubule-targeted research.

• HATU in Next-Generation Peptide Chemistry: Mechanistic Impac

  2026-04-16

  Explore the role of HATU in peptide synthesis chemistry, focusing on its mechanism, selectivity, and impact on functionalized inhibitor design. This article offers a unique, structure-guided perspective with insights not found in standard protocol guides.

• RapaLink-1: Advanced Third-Generation mTOR Inhibitor Workflo

  2026-04-15

  RapaLink-1 enables robust, protocol-backed inhibition of mTOR, overcoming resistance mutations and powering both cancer and developmental dormancy assays. Its bivalent action, superior potency, and reproducibility set new standards for glioma and embryonic stem cell workflows.

• Translating Wee1 Inhibition: MK-1775 at the Forefront of Can

  2026-04-14

  This thought-leadership piece examines the mechanistic and translational impact of MK-1775, a selective Wee1 kinase inhibitor, in modern cancer research. Integrating evidence from in vitro modeling, recent workflow advances, and the APExBIO product platform, we deliver actionable guidance for researchers seeking to optimize cell cycle checkpoint abrogation and p53-deficient tumor sensitization.

• Pseudo-UTP in mRNA Nanomedicine: Mechanistic Insights for Im

  2026-04-13

  Explore how pseudo-modified uridine triphosphate (Pseudo-UTP) transforms mRNA synthesis for advanced immunotherapy. This deep-dive illuminates its mechanistic role in RNA stability and translation, bridging the latest nanomedicine research with practical assay design.

• L-Ornithine (SKU B8919): Reliable Workflows in Metabolic Ass

  2026-04-13

  This article delivers evidence-based strategies for deploying L-Ornithine (SKU B8919) in cell viability, metabolic enzyme, and neurotoxicity assays. Addressing real laboratory scenarios, it demonstrates how APExBIO’s reagent provides data-backed reliability and workflow transparency for biomedical researchers.

• Saracatinib (AZD0530): Precision Src/Abl Inhibition in Cance

  2026-04-12

  Explore how Saracatinib (AZD0530) enables precise cell signaling dissection and advanced tumor growth inhibition in translational cancer research. This article uniquely bridges mechanistic insights and protocol guidance for experimental design.

15695 records 1/1047 page Next 12345 下5页 Last page